Pot stocks: Is now the time to invest in medical marijuana? – CBC.ca

i.cbc_.cain-the-news-apri-2d39f73bca4ce408300f2a6d8adef50a59dc6ea9

An air of optimism is brewing around Canada’s fledgling cannabis sector.

In Alberta, a cannabis company is breaking ground this week on an 800 square-foot, state-of-the-art medical marijuana greenhouse near Edmonton.

Then, another startup out of Okotoks will launch an online marketplace, called DooberExpress.com on Saturday.

But is now the right time to buy into the hype and invest in this growing industry?

Sean Mason, a senior editor with Small Cap Power, a website that reports on stocks, spoke with the Calgary Eyeopener Friday about the risks and rewards of the looming marijuana regulation.

Q. When did investors start paying attention to marijuana-related stocks?

A. I would say after Justin Trudeau became Prime Minister. He actually campaigned on legalizing marijuana, and since then these stocks have gone crazy up until last fall when they really seemed to peak … but now some of that air seems to have been let out.  

Q. Why did those stocks take a tumble?

A. I think a lot of it has to do with the uncertainty around what legalization is going to look like. All we know for sure is that it should be fully legal by Canada Day of 2018, but we don’t exactly know what that is going to mean — who is going to be able to sell it, who is going to be able to buy it, at what price.

Q. What are the risks of investing in these companies?

A. With early industries, there’s always operational risks for one thing — whether they can execute on what they say they are going to do

Until we know exactly what the regulation is in Canada, these stocks could continue to drift, possibly lower. But I think long term, the future is bright for at least some of the bigger companies in the industry.

Q. If the rule

Read More Here...

Posted in Hemp, MMJ, Cannabis Stocks News | Comments Off on Pot stocks: Is now the time to invest in medical marijuana? – CBC.ca

Pot Stocks Are Getting Ready for Recreational Marijuana – Profit Confidential

www.profitconfidential.co-757d929ed54901f2d471ca1d428d8f7961add2f5

Pot Stocks Position Themselves for the Future 

It’s not an easy game to play, relying on politicians to justify an investment. After all, it’s not exactly as if politicians are world renowned for being the most trustworthy folks on the planet. And that goes double for following through on promises, which makes the latest news about companies gearing up for the recreational marijuana market to go legal in Canada all the more interesting for pot stocks and their investors.

To give a refresher on what’s happening in Canada, the Liberal government under Prime Minister Justin Trudeau campaigned in 2015 on the promise that it would legalize all forms of marijuana use, including recreational. This would make Canada the first western nation to fully legalize the drug for public consumption. Therefore, a great many pot stocks in Canada have been reaping the benefits. (Source: “Liberals to announce marijuana will be legal by July 1, 2018,” CBC, March 26, 2017.)

But beyond those surface gains, there are larger implications at play that go beyond Canada and will affect the marijuana market in general. Many of these are centered on the pot stock companies themselves and how they’re gearing up to face the legal changes and the framework that will inform how the nation deals with weed sales.

Last time, we took a look at marketing marijuana in Canada and how the laws will shake out when it comes to regulations for weed advertisement. My argument there was that, while marijuana marketing may or may not have a massive effect on future sales, ultimately what is important to note is the tone of how legislators are approaching legalized weed.

For instance, if pot stocks are treated more like tobacco versus alcohol, that could have a dramatic effect on sales. And how Canadian legislators ultimately decide to handle the

Read More Here...

Posted in Hemp, MMJ, Cannabis Stocks News | Comments Off on Pot Stocks Are Getting Ready for Recreational Marijuana – Profit Confidential

Why Marijuana Stocks Will Benefit from Drone Deliveries – Money Morning

moneymorning.comweed-cann-098d94b7f43f53f1970727c9712c1f912f1083d5

Delivering legal cannabis is dangerous, as evidenced by a robbery on Jan. 29, 2016, in San Francisco, where thieves stole a delivery driver’s car and $8,000 worth of marijuana.

But a novel concept could increase the safety of cannabis deliveries and be a boon for marijuana stocks: drone deliveries. Not only will drone deliveries increase safety, but they will also make delivery faster and more convenient.

And we’ve found one company that’s harnessing the potential of drone deliveries in the medicinal marijuana industry.

We’ll get to how this company’s drone deliveries could increase sales for marijuana companies and help pot stock prices climb in just a bit. But we also have a special profit opportunity in the drone industry to share with our readers that could be creating $127 billion in new wealth as we speak.

But first, we want Money Morning readers to know more about the medical marijuana startup pioneering this revolutionary delivery system…

This One Startup Could Revolutionize the Marijuana Industry

Founded in 2013, Eaze partners with legal marijuana dispensaries to deliver cannabis to medical marijuana patients in California. Medical marijuana patients order cannabis products online through Eaze’s website and receive a text message when their driver is arriving.

According to its website, most deliveries take between 10 and 20 minutes.

BREAKING: New Legislation Could Turn Tiny Pot Stocks into Millions. Click Here…

However, the amount of deliveries and speed of marijuana transportation could soon drastically increase…

In April, Eaze demonstrated a marijuana drone delivery at the High Times Cannabis Cup in San Bernardino.

As you can see in the accompanying video, the drone was able to deliver marijuana to an attendee of the Cannabis Cup with pinpoint accuracy.

Video Drone Delivery of Marijuana Demonstration

Now, it’s true the technology still needs to be

Read More Here...

Posted in Hemp, MMJ, Cannabis Stocks News | Comments Off on Why Marijuana Stocks Will Benefit from Drone Deliveries – Money Morning

Monday Mailbag: Bullish Buffett, Bearish Soros, Risky Pot Stocks… and More – Investing Daily

As I answer your correspondence this week, the most influential missive in the investment realm comes to mind: Warren Buffett’s annual letter to shareholders.

Last year was prosperous for Buffett’s Berkshire Hathaway (NYSE: BRK.A), which saw its stock rise by 23.4%. Buffett now has an estimated net worth of $76.3 billion.

Fear of a market correction is a recurring theme in the letters that I get from readers. In his latest shareholder letter, Buffett offers this perspective:

“During such scary periods, you should never forget two things: First, widespread fear is your friend as an investor, because it serves up bargain purchases. Second, personal fear is your enemy. It will also be unwarranted. Investors who avoid high and unnecessary costs and simply sit for an extended period with a collection of large, conservatively financed American businesses will almost certainly do well.”

Buffett doesn’t even think that the stock market is in a bubble right now, which certainly makes him an outlier among analysts. With that reassuring context in mind, let’s get to your letters.

Soros takes a bearish turn…

“George Soros is predicting a market correction this year. Is he right?” — James H.

With deference to the eternal optimism of Warren Buffett, the consensus of most analysts, including our own team, is that this overvalued market will at some point experience a much-needed correction in 2017.

In addition to the Oracle of Omaha, it’s also worth heeding the views of George Soros. Hungarian-born Soros, the founder of the $4.5 billion Soros Fund Management LLC, currently has a net worth of $25.2 billion.

This uncannily prescient billionaire is known as “The Man Who Broke The Bank of England” because of his short sale of $10 billion worth of British pounds, generating him a profit of $1 billion during

Read More Here...

Posted in Hemp, MMJ, Cannabis Stocks News | Comments Off on Monday Mailbag: Bullish Buffett, Bearish Soros, Risky Pot Stocks… and More – Investing Daily

This Marijuana Stock Darling Crashed 17% in May – Motley Fool

g.foolcdn.comgw-pharma-gr-79eb01b53bd01076c5e0ec7bfb102ff9f481ebf8

What happened

Following comments from a competitor’s CEO that suggest competition for the company’s epilepsy drug is in the works, shares in GW Pharmaceuticals (NASDAQ:GWPH) tumbled by 17.2% in May, according to S&P Global Market Intelligence.

So what

GW Pharmaceuticals has made a name for itself by pioneering research into the use of marijuana-derived cannabinoids as medicine. The company already markets Sativex, a THC-based drug for muscle spasms in multiple sclerosis patients, and last year, it put up impressive trial results for Epidiolex, a cannabidiol drug being evaluated for use in childhood epilepsy patients.

IMAGE SOURCE: GW PHARMACEUTICALS.

Epidiolex reduced seizure rates by 40% from baseline in patients with Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of childhood-onset epilepsy. There’s a big need for new treatment options in tough-to-treat epilepsy indications, so unsurprisingly, Epidiolex’s performance sparked significant excitement from investors that sent GW Pharmacueticals’ share price soaring.

Recently, however, GW Pharmaceuticals shares have lost some of their luster. Industry watchers have begun to wonder if Epidiolex’s peak sales opportunity could be crimped by the availability of high-cannabidiol strains at marijuana dispensaries and future competition. Last month, Insys Therapeutics‘ (NASDAQ:INSY) new CEO, Saeed Motahari, assured investors that the company’s own research into the use of cannabidiol for pediatric epilepsy will continue.

Motahari summarized Insys Therapeutics’ plans (emphasis mine):

This year, we believe we are poised to grow our commercial portfolio from one to two products, file an NDA [New Drug Application] for buprenorphine, and significantly advance our pipeline of products across both our sublingual spray and cannabinoid platforms.

Now what

GW Pharmaceuticals’ management plans to file for approval of Epidiolex with the Food and Drug Administration soon, and if the process goes well, Epidiolex could be commercially available next year. That puts the company miles ahead of competitors like Insys Therapeutics. 

Read More Here...

Posted in Hemp, MMJ, Cannabis Stocks News | Comments Off on This Marijuana Stock Darling Crashed 17% in May – Motley Fool
« Older
Newer »